Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

45%

5 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

5(45.5%)

Phase 3

5(45.5%)

Phase 1

1(9.1%)

11Total

Phase 2(5)

Phase 3(5)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT03806426Phase 3Active Not Recruiting

Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

Role: lead

NCT04335032Phase 3Unknown

EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)

Role: lead

NCT04273997Phase 2Unknown

Metronidazole Ointment in Non-healing Pilonidal Sinus Wounds

Role: lead

NCT00420797Phase 3Withdrawn

A Study to Evaluate Topical Phenylephrine Gel in the Management of Faecal Incontinence

Role: lead

NCT00510692Phase 2Completed

Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA

Role: lead

NCT01217515Phase 3Completed

Diltiazem Hydrochloride Cream for Anal Fissure

Role: lead

NCT00984334Phase 2Completed

Naloxone SR Capsules in Patients With Opioid Induced Constipation

Role: lead

NCT00774722Phase 2Completed

A Randomised Controlled Trial of the Use of Topical Metronidazole (10%) to Reduce Pain After Haemorrhoidectomy

Role: lead

NCT00509639Phase 3Completed

Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease

Role: lead

NCT00432913Phase 2Completed

Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa

Role: lead

NCT00774969Phase 1Completed

Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease

Role: lead

All 11 trials loaded